NCT06097962View on ClinicalTrials.gov

Safety and Efficacy of NK510 to Treat NSCLC

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

July 1, 2026

Study Completion Date

July 1, 2026

Conditions
NSCLC
Interventions
DRUG

NK510

Intravenous infusion

DRUG

Tislelizumab，atezolizumab or sugemalimab

Administer according to the instructions

Trial Locations (1)

Unknown

RECRUITING

General Hospital of Eastern Theater Command, Nanjing

All Listed Sponsors
collaborator

The General Hospital of Eastern Theater Command

OTHER

lead

Base Therapeutics (Shanghai) Co., Ltd.

INDUSTRY